These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 31653572)

  • 1. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
    Zhang T; Karsh LI; Nissenblatt MJ; Canfield SE
    Clin Genitourin Cancer; 2020 Feb; 18(1):1-10. PubMed ID: 31653572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
    Scher HI; Lu D; Schreiber NA; Louw J; Graf RP; Vargas HA; Johnson A; Jendrisak A; Bambury R; Danila D; McLaughlin B; Wahl J; Greene SB; Heller G; Marrinucci D; Fleisher M; Dittamore R
    JAMA Oncol; 2016 Nov; 2(11):1441-1449. PubMed ID: 27262168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of AR-V7 and ARv
    Tagawa ST; Antonarakis ES; Gjyrezi A; Galletti G; Kim S; Worroll D; Stewart J; Zaher A; Szatrowski TP; Ballman KV; Kita K; Tasaki S; Bai Y; Portella L; Kirby BJ; Saad F; Eisenberger MA; Nanus DM; Giannakakou P
    Clin Cancer Res; 2019 Mar; 25(6):1880-1888. PubMed ID: 30301829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.
    Markowski MC; Frick KD; Eshleman JR; Luo J; Antonarakis ES
    Prostate; 2016 Dec; 76(16):1484-1490. PubMed ID: 27404039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review.
    Sciarra A; Gentilucci A; Silvestri I; Salciccia S; Cattarino S; Scarpa S; Gatto A; Frantellizzi V; Von Heland M; Ricciuti GP; Del Giudice F; Maggi M
    Medicine (Baltimore); 2019 May; 98(19):e15608. PubMed ID: 31083254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.
    Scher HI; Graf RP; Schreiber NA; Jayaram A; Winquist E; McLaughlin B; Lu D; Fleisher M; Orr S; Lowes L; Anderson A; Wang Y; Dittamore R; Allan AL; Attard G; Heller G
    JAMA Oncol; 2018 Sep; 4(9):1179-1186. PubMed ID: 29955787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor variant-driven prostate cancer II: advances in clinical investigation.
    Brown LC; Lu C; Antonarakis ES; Luo J; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):367-380. PubMed ID: 32094489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
    Maughan BL; Antonarakis ES
    Curr Treat Options Oncol; 2015 Dec; 16(12):57. PubMed ID: 26537882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AR-V7 and prostate cancer: The watershed for treatment selection?
    Ciccarese C; Santoni M; Brunelli M; Buti S; Modena A; Nabissi M; Artibani W; Martignoni G; Montironi R; Tortora G; Massari F
    Cancer Treat Rev; 2016 Feb; 43():27-35. PubMed ID: 26827690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
    Chen ZY; Dong Q; Liu LR; Wei Q
    Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
    Nakazawa M; Lu C; Chen Y; Paller CJ; Carducci MA; Eisenberger MA; Luo J; Antonarakis ES
    Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients.
    Worroll D; Galletti G; Gjyrezi A; Nanus DM; Tagawa ST; Giannakakou P
    Phys Biol; 2019 Mar; 16(3):036003. PubMed ID: 30763921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
    Del Re M; Biasco E; Crucitta S; Derosa L; Rofi E; Orlandini C; Miccoli M; Galli L; Falcone A; Jenster GW; van Schaik RH; Danesi R
    Eur Urol; 2017 Apr; 71(4):680-687. PubMed ID: 27733296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer.
    Luo J
    Asian J Androl; 2016; 18(4):580-5. PubMed ID: 27174161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest.
    Liu HE; Vuppalapaty M; Hoerner CR; Bergstrom CP; Chiu M; Lemaire C; Che J; Kaur A; Dimmick A; Liu S; Metzner TJ; Araya M; Crouse S; Sprenger-Haussels M; Schlumpberger M; Leppert JT; Hauch S; Sollier E; Fan AC
    BMC Cancer; 2024 Apr; 24(1):482. PubMed ID: 38627648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer].
    Büchler T; Bobek V; Kološtová K
    Klin Onkol; 2017; 31(1):9-14. PubMed ID: 29488772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.
    Lu C; Brown LC; Antonarakis ES; Armstrong AJ; Luo J
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):381-397. PubMed ID: 32139878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT
    Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
    To SQ; Kwan EM; Fettke HC; Mant A; Docanto MM; Martelotto L; Bukczynska P; Ng N; Graham LK; Parente P; Pezaro C; Mahon K; Horvath L; Todenhöfer T; Azad AA
    Eur Urol; 2018 Jun; 73(6):818-821. PubMed ID: 29398263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.